fsgs

AC1903 is a specific inhibitor of TRPC5 channel, and has been shown to suppress severe proteinuria and prevent podocyte loss.

APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.

Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1 2, p38, and AKT phosphorylation critical for immune responses. It disrupts the interaction between the βγ subunit of the Gi protein and downstream effectors linked to the fMLP receptor, thus abrogating fMLP-induced respiratory bursts. Additionally, larixol effectively reduces fMLP (0.1 μM)-triggered superoxide anion generation (IC50: 1.98 μM), cathepsin G secretion (IC50: 2.76 μM), and cellular chemotaxis, mitigating neutrophil hyperactivation and subsequent inflammation or tissue injury. Derivatives of larixol also demonstrate inhibitory activity on TRPC6 functional mutants associated with FSGS [1] [2].

Isomaltulose monohydrate is an fMLP inhibitor that also inhibits Src kinase, ERK1 2, p38, and AKT phosphorylation signals in immune regulation. It interferes with the interaction between the βγ subunit of the fMLP receptor Gi protein and downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Isomaltulose monohydrate inhibits fMLP (0.1 μM)-induced superoxide anion production (IC_{50< sub>: 1.98 μM), cathepsin G release (IC50< sub>: 2.76 μM), and chemotaxis. It can improve excessive activation of neutrophils and reduce inflammation or tissue damage. Derivatives of Isomaltulose monohydrate have been found to inhibit FSGS-related TRPC6 functional mutants [1].}